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(IISPV), Tarragona, Spain
9CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)- Instituto de Salud Carlos III, Madrid, Spain
10Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Centre, the 
Netherlands
This is an open access article under the terms of the Creat ive Commo ns Attri butio n- NonCo mmercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS).
Lucas Jurado- Fasoli, Xinyu Di, and Isabelle Kohler contributed equally to this work. 
Correspondence
Jonatan R. Ruiz and Borja Martinez- 
Tellez, PROmoting FITness and Health 
through Physical Activity Research Group 
(PROFITH), Sport and Health University 
Research Institute (iMUDS), Department 
of Physical Education and Sports, Faculty 
of Sport Sciences, University of Granada, 
Spain.
Email: ruizj@ugr.es and  
b.martinez-tellez@lumc.nl
Funding information
This study was supported by the 
Spanish Ministry of Economy and 
Competitiveness via the Fondo de 
Investigación Sanitaria del Instituto de 
Salud Carlos III (PI13/01393) and PTA- 
12264, Retos de la Sociedad (DEP2016- 
79512- R) and the European Regional 
Development Fund (ERDF), the Spanish 
Ministry of Education (FPU16/02828 
and FPU19/01609), the Fundación 
Abstract
Objective: Omega- 6 and omega- 3 oxylipins are known to play a role in inflammation 
and cardiometabolic diseases in preclinical models. The associations between plasma 
levels of omega- 6 and omega- 3 polyunsaturated fatty acid– derived oxylipins and 
body composition and cardiometabolic risk factors in young adults were assessed.
Methods: Body composition, brown adipose tissue, traditional serum cardiometabolic 
risk factors, inflammatory markers, and a panel of 83 oxylipins were analyzed in 133 
young adults (age 22.1[SD 2.2] years, 67% women).
Results: Plasma levels of four omega- 6 oxylipins (15- HeTrE, 5- HETE, 14,15- EpETrE, 
and the oxidative stress– derived 8,12- iso- iPF2α- VI) correlated positively with adiposity, 
prevalence of metabolic syndrome, fatty liver index, and homeostatic model assess-
ment of insulin resistance index and lipid parameters. By contrast, the plasma levels 
of three omega- 3 oxylipins (14,15- DiHETE, 17,18- DiHETE, and 19,20- DiHDPA) were 
negatively correlated with adiposity, prevalence of metabolic syndrome, fatty liver 
index, homeostatic model assessment of insulin resistance index, and lipid parameters. 
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INTRODUC TION
The global prevalence of obesity and cardiometabolic diseases has 
increased progressively in the past decades to reach pandemic pro-
portions (1). A major risk factor for cardiometabolic diseases is the 
so- called metabolic syndrome, which is defined as a constellation 
of metabolic disorders, including insulin resistance and impaired 
glucose tolerance, atherogenic dyslipidemia (high triglycerides [TG], 
total cholesterol [TC], and low- density lipoprotein cholesterol [LDL- 
C], and low high- density lipoprotein cholesterol [HDL- C]), and a pro-
inflammatory state accompanied by excess visceral adipose tissue 
(VAT) mass (2).
Omega- 6– and omega- 3– derived lipid mediators have a prom-
inent role in inflammation and cardiometabolic diseases as they 
possess pro- and anti- inflammatory properties (3,4). Omega- 6 and 
omega- 3 polyunsaturated fatty acids (PUFAs) are essential fatty 
acids (i.e., they should be obtained from the diet) because they can-
not be synthesized endogenously in humans (5). Upon dietary inges-
tion, circulating omega- 6 and omega- 3 PUFAs are used by almost all 
tissues and are oxidized by several enzymatic steps involving cyclo-
oxygenase, lipoxygenase, or cytochrome P450 enzymes (6). These 
enzymatic reactions facilitate the conversion of PUFAs to oxylipins 
and other bioactive lipids, which are major mediators of the pro- and 
anti- inflammatory effects of PUFAs on human metabolism (6).
Curiously, circulating oxylipin levels might not necessarily mimic 
dietary PUFA intake, because oxylipin production depends on en-
zyme preference for specific PUFAs (6). Oxylipins are reported 
to be produced by various tissues, including white adipose tissue, 
liver, kidney, and ileum (6). Additionally, brown adipose tissue (BAT), 
a metabolically active thermogenic tissue present in adult hu-
mans (7- 9), has been suggested to secrete omega- 6 (e.g., 5- HETE, 
5,6- EpETrE, 12,13- DiHOME) and omega- 3 (e.g., 12- HEPE) oxylipins 
(10- 13).
Iberoamericana de Nutrición (FINUT), 
the Redes Temáticas de Investigación 
Cooperativa RETIC (Red SAMID 
RD16/0022), the AstraZeneca HealthCare 
Foundation, the University of Granada 
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for Health Research and Development 
and the Royal Netherlands Academy 
of Sciences (CVON2017- 20 GENIUS- 2) 
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The panel of seven oxylipins predicted adiposity better than traditional inflammatory 
markers such as interferon gamma or tumor necrosis factor- alpha. Pathway analyses 
revealed that individuals with obesity had higher plasma levels of omega- 6 and lower 
plasma levels of omega- 3 oxylipins than normal- weight individuals.
Conclusion: Plasma levels of seven omega- 6 and omega- 3 oxylipins may have utility 
as early markers of cardiometabolic risk in young adults.
Study Importance
What is already known?
► Omega- 6 and omega- 3 oxylipins are breakdown prod-
ucts of polyunsaturated fatty acids, which play a role 
in inflammation and cardiometabolic diseases. The 
fat- 1 transgenic mouse, which transforms omega- 6 
into omega- 3 polyunsaturated fatty acids, is protected 
against cardiometabolic diseases and shows lower lev-
els of omega- 6 oxylipins, including 15- HeTrE, 5- HETE, 
and 14,15- EpETrE, and higher levels of omega- 3 ox-
ylipins, including 14,15- DiHETE, 17,18- DiHETE, and 
19,20- DiHDPA.
What does this study add?
► We show four omega- 6 oxylipins and three omega-
 3 oxylipins strongly related to body composition and 
cardiometabolic risk factors in young adults. These 
seven oxylipins are better predictors of adiposity than 
traditional pro- and anti- inflammatory markers and are 
identical to those previously described in the fat- 1 mice, 
suggesting a causal relationship. This set of oxylipins 
may be considered to diagnose cardiometabolic risk in 
young adults.
How might these results change the direction of 
research or the focus of clinical practice?
► Plasma levels of seven omega- 6 and omega- 3 oxylipins 
may have utility as early markers of cardiometabolic risk 
in young adults.
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Although omega- 6 oxylipins have proinflammatory, vasoconstric-
tor, and proliferative functions, all of which are involved in the progres-
sion of obesity and cardiometabolic diseases (6,14), omega- 3 oxylipins 
have the opposite effects (6,14). Notably, plasma levels of the omega- 6 
oxylipins 9,10- EpODE and 9,10- EpOME are higher in women with type 
2 diabetes than in nondiabetic peers (15). Likewise, plasma levels of 
omega- 6 (8,9- DiHETrE) and omega- 3 (5- HEPE and 10,11- DiHDPE) ox-
ylipins are higher in men with hyperlipidemia than in normolipidemic 
men (16). These studies support a relationship between omega- 6 ox-
ylipins and cardiometabolic disorders; however, the relationship be-
tween both omega- 6 and - 3 oxylipins and cardiometabolic risk factors 
in young, relatively healthy individuals has not yet been established.
Here we investigated the associations of plasma levels of ome-
ga- 6 and - 3 PUFA– derived oxylipins with body composition and 
cardiometabolic risk factors in a well- phenotyped cohort of young 
adults.
METHODS
See online Supporting Information for an extensive description of 
all methods.
Study design and participants
A total of 136 participants, including 91 women and 45 men (age 
22.1 [SD 2.2] years), were included in the present study (ACTIBATE; 
ClinicalTrials.gov ID: NCT02365129) (17). The ACTIBATE study en-
compassed multiple evaluation waves involving groups of 16 to 24 
individuals every 2 to 3 weeks in October, November, and December 
of 2015 and 2016. The study was approved by the Ethics Committee 
on Human Research of the University of Granada (n° 924) and the 
Servicio Andaluz de Salud and was in accordance with the princi-
ples of the latest version of the Declaration of Helsinki. Written 
informed consent was provided from all participants before their 
enrollment. Inclusion criteria were the following: (1) nonsmoking, (2) 
sedentary (i.e., <20 minutes of moderate- to- vigorous physical ac-
tivity on <3 days per week), (3) no acute or chronic illness, (4) no 
medication that might interfere with the assessments, and (5) not 
pregnant. Participants were requested to be rested, to abstain from 
moderate- to- vigorous physical activity, to use bus or car transporta-
tion, to refrain from stimulants and/or alcohol on the days of the 
measurements, and to have not performed any moderate exercise in 
the previous 24 hours or vigorous exercise in the previous 48 hours. 
A total of 133 participants were included in the main analyses; 3 
participants were excluded because of blood collection issues.
Anthropometric and body composition measurements
Body weight was measured to the nearest 0.1 kg and height to 
the nearest 0.1 cm, using a model 799 scale and a stadiometer, 
respectively (both from Seca), without shoes and with light cloth-
ing. BMI was calculated from weight and height (kilograms/meters 
squared). Waist circumference was measured at the minimum pe-
rimeter, at the end of a normal expiration, with the arms relaxed on 
both sides of the body. When the minimum perimeter could not be 
detected, measurements were taken just above the umbilicus, in a 
horizontal plane. Waist circumference was measured twice with a 
plastic tape measure; the two measures were averaged for further 
analyses.
Lean, fat, and VAT masses were measured by dual- energy x- ray 
absorptiometry using a Discovery Wi device (Hologic Inc.) equipped 
with analysis software (APEX version 4.0.2). Lean and fat mass indi-
ces were expressed as kilograms/meters squared; fat mass was also 
expressed as a percentage of body weight. Individuals were cate-
gorized according to their BMI as having normal weight (BMI <25.0 
kg/m2), overweight (BMI ≥25.0 kg/m2 and <30.0 kg/m2), or obesity 
(BMI ≥30.0 kg/m2) (18).
Assessment of 18F- fluorodeoxyglucose uptake by BAT
Briefly, the shivering threshold of each participant was determined 
following a personalized cooling protocol (19). Then 48 to 72 hours 
after the shivering threshold determination, participants were ex-
posed to a 2- hour personalized cooling procedure at 3.8°C above 
their individual shivering threshold. After 1 hour of cold exposure, 
a bolus of ~185 MBq of 18F- fluorodeoxyglucose (18F- FDG) was in-
travenously injected, and the water temperature was increased by 
1°C. If participants reported shivering, the water temperature was 
further increased by 1°C. After 2 hours of cold exposure, a static 
positron emission tomography/computed tomography (PET/CT; 
Siemens Biograph 16 PET- CT) scan was performed. CT acquisition 
was performed using a peak of 120 kV and PET acquisition with 
a scan time of 6 minutes per bed position. PET/CT images were 
obtained from the atlas (i.e., cervical vertebra 1) to approximately 
the midchest. BAT- related outcomes were calculated as described 
(20- 22).
Blood sample collection and determination of 
cardiometabolic risk factors
Blood was collected after an overnight (10 hours) fast, between 8:00 
and 9:00 am, and at room temperature (20°C to 24°C). Blood was 
drawn from the antecubital vein and was immediately centrifuged to 
obtain serum (obtained with Vacutainer SST II Advance tubes, VWR 
International, LLC) and plasma (obtained with Vacutainer Hemogard 
tubes, containing the K2 potassium salt of ETDA as anticoagulant). 
Samples were aliquoted and stored at −80°C.
Traditional cardiometabolic risk factors and inflammatory mark-
ers were measured in serum (glucose, insulin, cortisol, TC, HDL- C, 
TG, apolipoproteins A and B, glutamic pyruvic transaminase [GTP], 
gamma- glutamyl transferase [GGT], alkaline phosphatase [ALP], 
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C- reactive protein, complement C3, complement C4, leptin, adi-
ponectin, interleukin [IL]- 2, IL- 4, IL- 6, IL- 7, IL- 8, IL- 10, IL- 17a, inter-
feron gamma [IFNɣ], and tumor necrosis factor- alpha [TNFα]).
Metabolic syndrome prevalence was calculated following the 
National Cholesterol Education Program Adult Treatment Panel III 
(ATP III) (23) and International Diabetes Federation (IDF) classifica-
tions (24). Insulin sensitivity was estimated via the homeostatic model 
assessment of insulin resistance index (HOMA- IR) (25), and the fatty 
liver index was determined as a proxy of hepatic steatosis (26).
Determination of plasma oxylipins
Oxylipins were determined by liquid chromatography- tandem mass 
spectrometry (LC- MS/MS) (27). The LC- MS/MS protocol enabled 
the relative quantitation of 83 oxylipins from the conversion of the 
omega- 6 PUFAs linoleic acid (LA), dihomo- γ- linolenic acid (DGLA), 
and arachidonic acid (AA), as well as the omega- 3 PUFAs α- linolenic 
acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid 
(DHA). The oxylipins that can be detected by this method are listed 
in Supporting Information Table S1. Of the 50 oxylipins detected, 40 
showed a low analytical variability with relative standard in quality 
control (QCRSD) ≤ 15%, and 10 showed a moderate variability be-
tween 15% < QCRSD ≤ 40% (Supporting Information Table S1).
Statistical analyses
The baseline characteristics and outcomes of the study participants 
were expressed as mean (SD). The normal distribution assump-
tion was tested using the Shapiro– Wilk test, visual histograms, and 
Q– Q plots. Non- normally distributed variables (traditional car-
diometabolic and inflammatory markers and oxylipins) were log10- 
transformed before further analysis. We performed all the analyses 
divided by men and women, and similar patterns were observed. 
Moreover, we studied whether significant interactions were pre-
sented between the plasma oxylipin levels and body composition 
and cardiometabolic risk parameters using linear regression models, 
and no sex interactions were observed (all p ≥ 0.05). Thus, data of 
men and women were analyzed together.
We conducted Pearson correlation analyses to examine the re-
lationship between plasma levels of oxylipins and body composition 
and cardiometabolic risk parameters. All p values were corrected 
by the two- stage step- up procedure of Benjamini, Krieger, and 
Yekutieli for multiple comparisons by controlling the false discov-
ery rate (FDR) (28). Plasma omega- 6 and omega- 3 oxylipins were 
both weakly correlated with PUFA, fish, and shellfish intake (data 
not shown). We therefore performed partial correlations of plasma 
levels of oxylipins with body composition and cardiometabolic risk 
parameters adjusting for dietary energy, PUFA, fish, and shellfish 
intake. Pearson correlation analyses were also carried out between 
plasma levels of oxylipins and traditional inflammatory parameters. 
As secondary analyses, we examined the relationship between 
body composition and cardiometabolic risk factors. All correlation 
analyses and plots were designed using the “corrplot” package in 
R software version 3.6.0 (R Foundation for Statistical Computing). 
Forward stepwise regression was performed using fat mass per-
centage and VAT mass as dependent outcomes in separate models. 
The measured oxylipins persisting after FDR correction (i.e., 15- 
HETrE, 5- HETE, 14,15- EpETrE, 8,12- iso- iPF2α- VI, 14,15- DiHETE, 
17,18- DiHETE, and 19,20- DiHDPA), together with the traditional 
cardiometabolic risk factors HOMA- IR, GTP, GGT, ALP, TC, HDL- C, 
TG, cortisol, adiponectin, and leptin, were introduced as predictors 
using a forward stepwise procedure, which introduces the predict-
ing components step- by- step into the model (if p < 0.05) according 
to the strength of their association with the dependent outcome. 
We repeated the same analyses including plasma levels of oxylipins 
and traditional pro- and anti- inflammatory markers as predictors 
of fat mass percentage and VAT mass. The forward stepwise re-
gression was performed using the SPSS Statistics version 25.0 (IBM 
Corp.).
Differences in plasma levels of oxylipins across BMI categories 
(normal weight, overweight, and obesity) were assessed with met-
abolic pathway analyses using Cytoscape software version 3.7.0 
(Cytoscape Consortium) (29). We calculated a fold change for each 
oxylipin as the ratio between the oxylipin level in individuals with 
obesity divided by the oxylipin level in normal- weight individuals, as 
well as between obesity and overweight and between overweight 
and normal weight. Independent t test analyses were performed for 
between- group comparisons. The level of significance was set at p < 
0.05, using SPSS version 25.0.
RESULTS
The descriptive characteristics of the participants are presented in 
Table 1. A total of 50 of the 83 detectable PUFA- derived omega- 6 
(n = 30) and omega- 3 (n = 20) oxylipins, including their precursors, 
were detected in fasting plasma samples (Supporting Information 
Table S1). Baseline plasma levels of each oxylipin measured in the 
participants are listed in Supporting Information Table S2.
Plasma levels of oxylipins are related to body 
composition parameters
At the first step, we investigated the relationship between the 
plasma levels of omega- 6 and omega- 3 oxylipins and body composi-
tion parameters. A total of 12 of the 30 detected omega- 6 oxylipins 
correlated positively with fat mass percentage (all r ≥ 0.18; p < 0.05; 
Figure 1A), whereas 3 of the 20 detected omega- 3 oxylipins cor-
related negatively with fat mass percentage (all r ≤ −0.29; p < 0.05; 
Figure 1B). Similar correlation coefficients were obtained between 
the aforementioned oxylipins and fat mass index or VAT mass (all r 
≤ −0.23; p < 0.05; Figure 1A,B). After FDR correction, four omega- 6 
oxylipins (15- HeTrE, 5- HETE, 14,15- EpETrE, and 8,12- iso- iPF2α- VI) 
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TA B L E  1  Characteristics of the participants
n Total n Men n Women
Age (y) 136 22.1 (2.2) 45 22.3 (2.3) 91 21.9 (2.2)
Body composition
BMI (kg/m2) 136 24.9 (4.6) 45 26.8 (5.5) 91 23.9 (3.7)
Lean body mass (kg) 136 41.8 (9.7) 45 52.8 (7.2) 91 36.3 (5.0)
Lean mass index (kg/m2) 136 14.7 (2.4) 45 17.2 (2.1) 91 13.5 (1.4)
Fat body mass (kg) 136 24.7 (8.8) 45 24.8 (11.0) 91 24.6 (7.5)
Fat mass (%) 136 35.5 (7.6) 45 29.7 (7.6) 91 38.3 (5.9)
Fat mass index (kg/m2) 136 8.8 (3.0) 45 8.1 (3.6) 91 9.1 (2.7)
Visceral adipose tissue mass (g) 136 336.4 (174.1) 45 417.9 (175.9) 91 296.1 (159.2)
Waist circumference (cm) 130 81.0 (4.6) 43 89.9 (15.2) 87 76.5 (10.5)
BAT
BAT volume (mL) 131 68.5 (57.4) 42 78.9 (66.0) 89 63.6 (52.6)
BAT metabolic activity 131 332.9 (328.7) 42 326.8 (327.8) 89 335.8 (331.0)
BAT SUVmean 131 3.7 (1.9) 42 3.2 (1.3) 89 4.0 (2.1)
BAT SUVpeak 131 11.1 (8.2) 42 9.9 (7.3) 89 11.6 (8.6)
BAT SUVmax 131 12.2 (9.0) 42 10.8 (8.1) 89 12.8 (9.4)
Cardiometabolic risk factors
Metabolic syndrome ATP III 128 0.5 (0.9) 42 1.0 (1.3) 86 0.2 (0.5)
Metabolic syndrome IDF 128 0.7 (1.1) 42 1.1 (1.5) 86 0.5 (0.7)
Fatty liver index 132 20.4 (25.0) 43 36.9 (32.0) 89 12.5 (15.7)
GTP (IU/L) 131 19.0 (17.5) 43 28.4 (26.8) 88 14.4 (6.7)
GGT (IU/L) 131 19.8 (20.0) 43 29.9 (29.8) 88 14.9 (9.9)
ALP (IU/L) 132 71.3 (18.5) 43 79.3 (19.4) 89 67.5 (16.9)
C- reactive protein (mg/L) 132 2.4 (3.4) 43 2.1 (2.3) 89 2.5 (3.8)
C3 (mg/dL) 132 137.4 (23.8) 43 143.0 (26.2) 89 134.7 (22.2)
C4 (mg/dL) 132 28.7 (8.8) 43 30.3 (9.9) 89 27.9 (8.1)
Glucose (mg/dL) 132 87.6 (6.6) 43 88.9 (7.4) 89 87.0 (6.1)
Insulin (µIU/mL) 132 8.3 (4.9) 43 9.1 (6.4) 89 8.0 (4.0)
HOMA- IR 132 1.8 (1.2) 43 2.1 (1.6) 89 1.7 (1.0)
Insulin glucose ratio 132 14.1 (7.0) 43 14.8 (8.8) 89 13.8 (6.0)
Total cholesterol (mg/dL) 132 165.1 (32.2) 43 160.1 (30.9) 89 167.6 (32.7)
HDL- C (mg/dL) 132 52.8 (11.0) 43 46.0 (7.4) 89 56.0 (11.0)
LDL- C (mg/dL) 132 96.0 (25.3) 43 96.5 (26.2) 89 95.8 (25.0)
APOA1 (mg/dL) 113 144.7 (27.5) 37 130.0 (16.8) 76 151.9 (28.9)
APOB (mg/dL) 113 69.7 (19.9) 37 72.7 (24.4) 76 68.3 (17.3)
Triglycerides (mg/dL) 132 82.5 (44.6) 43 88.2 (47.2) 89 79.7 (43.2)
Leptin (µg/L) 129 6.2 (4.4) 42 4.4 (4.0) 87 7.1 (4.3)
Adiponectin (mg/L) 127 11.4 (7.9) 42 7.7 (5.2) 85 13.3 (8.3)
Systolic blood pressure (mmHg) 134 116.7 (11.6) 44 125.3 (10.9) 90 112.5 (9.5)
Diastolic blood pressure 
(mmHg)
134 70.9 (7.6) 44 72.2 (9.2) 90 70.3 (6.7)
Inflammatory parameters
IL- 2 (pg/mL) 109 2.4 (1.4) 37 2.0 (1.3) 72 2.6 (1.5)
IL- 4 (pg/mL) 109 13.1 (9.7) 37 11.7 (9.5) 72 13.8 (9.7)
IL- 6 (pg/mL) 109 1.6 (1.6) 37 1.6 (1.8) 72 1.6 (1.5)
IL- 7 (pg/mL) 109 4.0 (2.8) 37 3.3 (2.2) 72 4.4 (3.0)
(Continues)
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and three omega- 3 oxylipins (14,15- DIHETE, 17,18- DIHETE, and 
19,20- DiHDPA) remained significantly correlated with adiposity pa-
rameters (fat mass percentage, fat mass index, and VAT mass; all p < 
0.05; Figure 1A,B).
Given the clear link between plasma oxylipins and dietary PUFA 
intake (30), we next conducted partial correlation analysis adjusting 
for dietary energy, PUFA, fish, and shellfish intake as cofounders. 
We found that the significant correlations between the set of four 
omega- 6 and three omega- 3 oxylipins with adiposity parameters 
remained significant (Supporting Information Figure S1), suggesting 
that these correlations are not affected by dietary energy, PUFA, 
fish, and shellfish intake.
Because BAT can be a source of oxylipins (10- 13) and has been 
linked to a healthier cardiometabolic profile in humans (31), we 
explored whether plasma oxylipin levels correlated with BAT vol-
ume and activity. After FDR correction, plasma levels of the ome-
ga- 3 oxylipins 14,15- DiHETE, 17,18- DiHETE, 19,20- EpDPE, and 
19,20- DiHDPA correlated negatively with BAT volume and activity 
n Total n Men n Women
IL- 8 (pg/mL) 109 1.6 (0.8) 37 1.5 (0.9) 72 1.6 (0.8)
IL- 10 (pg/mL) 109 2.9 (3.6) 37 2.3 (2.1) 72 3.2 (4.1)
IFN- γ (pg/mL) 109 12.9 (5.4) 37 11.5 (5.5) 72 13.5 (5.3)
TNFα (pg/mL) 109 1.8 (1.1) 37 1.5 (0.7) 72 1.9 (1.2)
Data are presented as mean (SD).
Abbreviations: ALP, alkaline phosphatase; APOA1, apolipoprotein A1; APOB, apolipoprotein B; ATP III, Adult Treatment Panel III; BAT, brown 
adipose tissue; C3, complement C3; C4, complement C4; GGT, gamma- glutamyl transferase; GTP, glutamic pyruvic transaminase; HDL- C, high- 
density lipoprotein cholesterol; HOMA- IR, homeostatic model assessment of insulin resistance index; IDF, International Diabetes Federation; IFN- γ, 
interferon gamma; IL, interleukin; LDL- C, low- density lipoprotein cholesterol; SUV, standardized uptake value; TNFα, tumor necrosis factor- alpha.
TA B L E  1  (Continued)
F I G U R E  1  Pearson correlation analyses between plasma levels of oxylipins (omega- 6 and omega- 3) with body composition and brown 
adipose tissue (BAT) parameters in young adults (n = 133). Every box represents a significant correlation coefficient (all p < 0.05), whereas 
empty spaces represent no significant correlations. Blue and red boxes indicate positive and negative correlations, respectively. All oxylipin 
outcomes were log10- transformed prior to data analysis. *Significant after false discovery rate corrections. SUV, standardized uptake value. 
The abbreviations used for each oxylipin are detailed in Supporting Information Table S1
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(BAT metabolic activity, SUVmean, SUVpeak, and SUVmax; all r ≤ 
−0.23; p < 0.05; Figure 1B). By contrast, no significant correlations 
were found between plasma omega- 6 oxylipins and BAT volume or 
activity (Figure 1A). Of note, the associations remained unaltered 
when dietary intake (i.e., energy, PUFA, fish, and shellfish intake; 
Supporting Information Figure S1) and the seasonal variation were 
included as cofounders, the latter of which is known to affect the 
determination of BAT volume and activity in humans (31,32) (data 
not shown).
Plasma levels of oxylipins are related to 
cardiometabolic risk factors
We next examined whether plasma oxylipin levels were related to 
traditional cardiometabolic risk factors assessed in serum. Notably, 
the set of four omega- 6 oxylipins that correlated positively with 
adiposity parameters (15- HeTrE, 5- HETE, 14,15- EpETrE, and 
8,12- iso- iPF2α- VI) also correlated positively with an adverse cardi-
ometabolic profile (i.e., higher prevalence of metabolic syndrome, 
higher fatty liver index, serum glucose, and serum lipid parameters 
[TC or TG]; r ≥ 0.18; p < 0.05; Figure 2A). By contrast, the set of three 
omega- 3 oxylipins that correlated negatively with adiposity param-
eters (14,15- DIHETE, 17,18- DIHETE, and 19,20- DiHDPA) corre-
lated with a favorable cardiometabolic profile, specifically lower 
prevalence of metabolic syndrome, fatty liver index, serum glucose, 
and serum lipid parameters (TC or TG) (p < 0.05; Figure 2B). The 
correlations remained significant after adjusting for dietary energy, 
PUFA, fish, and shellfish intake (Supporting Information Figure S2), 
although they were not significant after correcting for FDR.
Based on the pro- and anti- inflammatory effects of the ome-
ga- 6 and omega- 3 oxylipins, respectively, we expected to observe 
significant correlations with traditional pro- and anti- inflammatory 
markers (IL- 2, IL- 4, IL- 6, IL- 7, IL- 8, IL- 10, IL- 17a, IFNɣ, and TNFα). We 
found that plasma levels of three of the four omega- 6 oxylipins that 
correlated positively with adiposity parameters and an adverse 
cardiometabolic profile (15- HeTrE, 5- HETE, and 8,12- iso- iPF2α- VI) 
also correlated positively with the proinflammatory markers IL- 17, 
IFNɣ, and TNFα and negatively with the anti- inflammatory marker 
IL- 4. Surprisingly, we found that the plasma levels of the three 
F I G U R E  2  Pearson correlation analyses between plasma levels of oxylipins (omega- 6 and omega- 3) with cardiometabolic risk factors in 
young adults (n = 133). Every box represents a significant correlation coefficient (all p < 0.05), whereas empty spaces represent no significant 
correlations. Blue and red boxes indicate positive and negative correlations, respectively. All oxylipin outcomes were log10- transformed prior to 
data analysis. *Significant after false discovery rate corrections. ALP, alkaline phosphatase; APOA1, apolipoprotein A1; APOB, apolipoprotein B; 
ATP III, National Cholesterol Education Program Adult Treatment Panel III; GGT, gamma- glutamyl transferase; GTP, glutamic pyruvic transaminase; 
HDL- C, high- density lipoprotein cholesterol; HOMA- IR, homeostatic model assessment of insulin resistance index; IDF, International Diabetes 
Federation; LDL- C, low- density lipoprotein cholesterol. The abbreviations used for each oxylipin are detailed in Supporting Information Table S1
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omega- 3 oxylipins that correlated negatively with adiposity param-
eters (14,15- DIHETE, 17,18- DIHETE, and 19,20- DiHDPA) did not 
correlate with traditional pro- and anti- inflammatory makers (all r ≥ 
0.19; p < 0.05; Supporting Information Figure S3B).
Given these findings, we used stepwise linear regression models 
to assess whether plasma levels of oxylipins were better predictors 
of adiposity than traditional cardiometabolic risk factors or estab-
lished pro- and anti- inflammatory markers. We selected the four 
omega- 6 and 3 omega- 3 oxylipins that were related to adiposity 
and cardiometabolic risk parameters (Figure 1A,B, Figure 2A,B, and 
Figure 3). The panel of seven oxylipins was included together with 
classical cardiometabolic risk factors as independent outcomes, and 
fat mass percentage or VAT mass was included as dependent out-
comes in separate models (Supporting Information Table S3). We re-
peated these analyses including the panel of oxylipins together with 
established pro- and anti- inflammatory markers as independent out-
comes (Table 2). Overall, the traditional cardiometabolic risk factors, 
principally leptin and HOMA- IR, were found to be better predictors 
of adiposity (fat mass percentage and VAT mass) than the panel of 
seven oxylipins (Supporting Information Table S3). However, the 
plasma levels of the omega- 6 oxylipins 5- HETE and 15- HETrE and 
the plasma levels of 14,15- DiHETE and 17,18- DiHETE (omega- 3 
oxylipins) were better predictors of adiposity than established pro- 
and anti- inflammatory markers (e.g., IL- 6, TNFα) (Table 2), predicting 
up to 27.2% and 22.9% of the explained variance of the fat mass 
percentage and VAT mass, respectively (Table 2). The stepwise linear 
regression models were repeated with the inclusion of all oxylipins, 
resulting in similar results to those observed with the panel of seven 
oxylipins (data not shown).
Individuals with obesity have higher plasma 
levels of omega- 6 and lower plasma levels of omega- 3 
oxylipins than normal- weight individuals
To further investigate the relationship between plasma levels of ox-
ylipins and adiposity and cardiometabolic risk factors, we performed 
pathway interaction network analyses comparing plasma levels of 
oxylipins between individuals with obesity and normal- weight in-
dividuals (Figure 4). We found that the metabolic pathway related 
to omega- 6 oxylipins, which includes DGLA, 8- HETrE, 15- HETrE, 
8,12- iso- iPF2α- VI, 14,15- EpETrE, and 15- HETE, was higher in indi-
viduals with obesity (n = 20) than in normal- weight (n = 82) indi-
viduals (fold change 1.26 to 1.47; p ≤ 0.005; Figure 4A). By contrast, 
F I G U R E  3  Scatterplots between plasma levels of selected oxylipins (15- HETrE, 5- HETE, 14,15- EpETrE, 8,12- iso- iPF2α- VI, 14,15- DiHETE, 
17,18- DiHETE, and 19,20- DiHDPA) and VAT, FLI, TG, and HOMA- IR. Pearson correlations were performed. All oxylipins values and 
triglycerides were log10- transformed. FLI, fatty liver index; HOMA- IR, homeostatic model assessment of insulin resistance index; TG, 
triglycerides; VAT, visceral adipose tissue. The abbreviations used for each oxylipin are detailed in Supporting Information Table S1
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TA B L E  2  Forward stepwise regression models assessing the independent association of the predictors (selected oxylipins and traditional 
pro- and anti- inflammatory markers) with fat mass percentage and visceral adipose tissue mass as dependent outcomes in separate models 
in young adults
β B 95% CI p (coefficients) R2 R2 change F change p (model)
Fat mass percentage (%)
Step 1 0.167 – 22.457 <0.001
14,15- DiHETE −0.409 −16.588 −23.523, −9.652 <0.001
Step 2 0.272 0.105 16.078 <0.001
14,15- DiHETE −0.390 −15.831 −22.353, −9.309 <0.001
5- HETE 0.325 11.815 5.976, 17.654 <0.001
Step 3 0.308 0.035 5.641 <0.001
14,15- DiHETE −0.398 −16.148 −22.545, −9.752 <0.001
5- HETE 0.311 11.284 5.545, 17.022 <0.001
IL- 8 0.189 6.048 1.001, 11.095 0.019
Visceral adipose tissue mass (g)
Step 1 0.126 – 16.211 <0.001
17,18- DiHETE −0.356 −323.799 −483.141, −164.456 <0.001
Step 2 0.229 0.103 14.846 <0.001
17,18- DiHETE −0.333 −303.105 −453.818, −152.392 <0.001
15- HETrE 0.322 336.505 163.444, 509.567 <0.001
Selected oxylipins: 15- HETrE, 5- HETE, 14,15- EpETrE, 8,12- iso- iPF2α- VI, 14,15- DiHETE, 17,18- DiHETE, and 19,20- DiHDPA; and traditional 
inflammatory markers: IL- 2, IL- 4, IL- 6, IL- 7, IL- 8, IL- 10, IL- 17a, IFNɣ, and TNFα.
Abbreviations: β, standardized regression coefficient; B, unstandardized regression coefficient; IL- 8, interleukin- 8; R2, adjusted coefficient of 
determination, expressing the percent variability of the dependent variable explained by each model; R2 change, additional percent variability 
explained by the model due to the inclusion of the new term.
F I G U R E  4  Interaction network pathway analyses of plasma levels of omega- 6 and omega- 3 polyunsaturated fatty acids in individuals 
with obesity versus normal- weight individuals. The networks depict the differences of individual (A) omega- 6 and (B) omega- 3 lipid 
mediators in obesity compared with normal- weight individuals. Blue boxes with yellow frame and red boxes with yellow frame indicate 
higher and lower levels, respectively, in both populations. Blue and red boxes without yellow frame are oxylipins without statistical 
significance. Enzymes involved in the metabolic pathway are represented in green. All oxylipin outcomes were log10- transformed prior to 
data analysis. Oxylipins without boxes were not detected (ND) or not measured (NM). The abbreviations used for each oxylipin are detailed 
in Supporting Information Table S1 
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the omega- 3 metabolic pathway tended to be lower in people with 
obesity, although only the plasma levels of 19,20- DiHDPA reached 
the significance threshold (fold change 0.81; p = 0.014; Figure 4B).
DISCUSSION
We identified seven oxylipins as potential subclinical markers of ad-
verse cardiometabolic health in young adults. Using targeted me-
tabolomics, we found that the plasma levels of 15- HeTrE, 5- HETE, 
14,15- EpETrE, and 8,12- iso- iPF2α- VI omega- 6 oxylipins were positively 
correlated with adiposity, the prevalence of metabolic syndrome, fatty 
liver index, HOMA- IR, and lipid parameters, whereas the plasma lev-
els of 14,15- DiHETE, 17,18- DiHETE, and 19,20- DiHDPA omega- 3 
oxylipins were negatively correlated with adiposity, the prevalence 
of metabolic syndrome, fatty liver index, and HOMA- IR and lipid pa-
rameters. The panel of seven oxylipins was a better predictor of adi-
posity than traditional pro- and anti- inflammatory markers (e.g., IFNɣ, 
TNFα). We also found that obesity was linked to higher plasma levels of 
omega- 6 and lower plasma levels of omega- 3 oxylipins.
Role of oxylipins in the development of adiposity and 
cardiometabolic diseases
Our data show that the plasma levels of a panel of seven oxylipins may 
be used as an early marker of cardiometabolic risk in young adults. 
Evidence in support of this notion comes from preclinical studies using 
the fat- 1 transgenic mouse, which expresses an omega- 3 desaturase 
that transforms omega- 6 into omega- 3 PUFAs and overcomes the en-
zymatic competition between omega- 6 and omega- 3 (33). This mouse 
model is protected against obesity and cardiometabolic diseases such 
as insulin resistance, liver steatosis, metabolic syndrome, and chronic 
inflammation when exposed to high- fat diet (34) and it shows lower 
plasma levels of omega- 6 oxylipins, including 15- HeTrE, 5- HETE, and 
14,15- EpETrE, and higher plasma levels of omega- 3 oxylipins, including 
14,15- DiHETE, 17,18- DiHETE, and 19,20- DiHDPA (35). Accordingly, 
the set of oxylipins described in fat- 1 mice is identical to the panel of 
oxylipins found in our human study, supporting their role as important 
players in metabolic homeostasis. The authors of the latter study sug-
gested that this oxylipin panel might be used as a potential marker of 
the cardiometabolic risk status of mice (35), which is confirmed in the 
present human cohort. Indeed, the aforementioned preclinical study 
supports the notion that the balance between omega- 6 and omega-
 3 oxylipins is the likely main mechanism that explains the protective 
phenotype, adding weight to the idea that the observational findings in 
the present study may be due to causal relationships. It is worth high-
lighting that 8,12- iso- iPF2α- VI is a potential marker of cardiometabolic 
health in humans; this omega- 6 oxylipin 8,12- iso- iPF2α- VI is produced 
by the nonenzymatic oxidation of membrane- linked AA and is a marker 
of free radical attack/oxidative stress (36). Evidence for its role in met-
abolic disorders was recently supplied by the observation that people 
with type 2 diabetes have higher levels of 8,12- iso- iPF2α- VI than those 
without (37), which is consistent with our findings. Accordingly, we 
found that 8,12- iso- iPF2α- VI was associated with increased indices of 
adiposity and with cardiovascular markers, which are linked to perma-
nent prooxidative stress, ultimately leading to systemic/local damage 
and clinical cardiovascular disease.
Role of oxylipins as potential markers of the overall 
inflammatory status
Our study establishes a panel of seven oxylipins as good markers 
of subclinical inflammation even before observed changes to proin-
flammatory cytokines, which are associated with increased adipose 
tissue accretion. This panel was related to adiposity and showed a 
coherent relationship with proinflammatory and anti- inflammatory 
cytokines, before the traditional inflammatory markers, such as IFNɣ 
or TNFα, emerged as indicators of a chronic inflammatory environ-
ment. It is well known that lipoxins, which are formed from omega- 6 
PUFA breakdown, include several proinflammatory lipid mediators 
such as prostaglandins, thromboxane, and leukotrienes. By contrast, 
breakdown of omega- 3 PUFAs produces specialized proresolving 
lipid mediators such as resolvins, maresins, and protectins, which 
regulate anti- inflammatory processes and allow for reestablishment 
of tissue homeostasis. Indeed, oxylipins influence cytokine produc-
tion and release, the coagulation cascade, and leukocyte chemotaxis 
(38,39), supporting their role as early contributors to the low- grade 
systemic inflammatory status in young adults.
Omega- 3 oxylipins are related to low 18F- FDG uptake 
by BAT
We observed that plasma levels of the omega- 3 oxylipins 
14,15- DiHETE, 17,18- DiHETE, 19,20- EpDPE, and 19,20- DiHDPA 
were negatively correlated with BAT volume and activity, whereas 
omega- 6 oxylipins showed no association with BAT- related out-
comes. BAT is a metabolic tissue with thermogenic and cardiometa-
bolic protective functions (31). Therefore, our findings are of clinical 
interest because of the secretory function of BAT, which might con-
tribute to the pool of circulating oxylipins (10- 13), although it can-
not be confirmed in the current study. At first glance, these findings 
would appear at odds with earlier studies showing that BAT has a 
role in the regulation of the systemic pool of omega- 3 and - 6 ox-
ylipins after cold exposure, increasing the levels of the former and 
decreasing the levels of the latter (10,11,40). It should be noted, 
however, that previous studies measured oxylipin levels before and 
after either a cold exposure or a single bout of exercise in small co-
horts (all n ≤ 40) (10,11,12,13,41), and none of them measured fast-
ing levels of oxylipins, as was done here. Therefore, comparisons 
between the present findings and those of earlier studies must be 
made carefully. Regarding the biological significance of the set of 
negative correlations we observed, it is known that the heart con-
sumes both glucose and fatty acids and that it can switch between 
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glycolytic or lipolytic- based pathways depending on the availability 
of substrates (42). BAT also consumes both glucose and fatty acids 
(43), but it is not yet known whether it has the ability to switch be-
tween oxidative and glycolytic metabolism contingent on substrate 
availability. On the basis of our observations, we are tempted to 
speculate that human BAT may have the ability to switch metabo-
lism, as we observed that glucose levels did not correlate with BAT- 
related outcomes (data not shown), whereas omega- 3 oxylipins, 
which were higher in abundance in plasma, negatively correlated 
with BAT- related outcomes. Further studies are needed to investi-
gate whether this hypothesis is plausible.
Curiously, 12,13- DiHOME is an LA- derived oxylipin secreted by 
BAT upon cold exposure and exercise (12,13), although in our study, 
plasma levels of 12,13- DiHOME did not correlate with BAT- related 
outcomes. In addition, we found that plasma levels of this oxylipin 
were not related to adiposity and cardiometabolic risk factors of 
young individuals, whereas it was negatively correlated with lean 
mass. This finding does not concur with previous evidence showing 
a negative relationship between the plasma levels of 12,13- DiHOME 
and BMI and fat mass (12,13), suggesting that more research is 
needed to understand the use of 12,13- DiHOME as marker of BAT 
activity and/or metabolic health in humans.
Limitations
As with all cross- sectional studies, the present study does not allow 
the establishment of causality; however, there are preclinical studies 
(35,44) supporting the causative role of oxylipins in the development 
of cardiometabolic diseases. The method for quantifying BAT volume 
and activity has several limitations, which are described elsewhere 
(43,45), and the data should therefore be interpreted carefully. The 
study population included sedentary young adults, which does not 
allow extrapolation of the findings to older, younger, or unhealthy 
populations, but it is, as far as we are aware, the only study performed 
so far. Thus, future studies are needed to evaluate whether these 
seven oxylipins are markers of cardiometabolic health in aged popula-
tions or populations at risk of cardiometabolic diseases.
CONCLUSION
We describe for the first time, to our knowledge, that plasma levels 
of four omega- 6 oxylipins (15- HeTrE, 5- HETE, 14,15- EpETrE, and 
8,12- iso- iPF2α- VI) positively correlate with adiposity and an adverse 
cardiometabolic profile, whereas the plasma levels of three omega-
 3 oxylipins (14,15- DiHETE, 17,18- DiHETE, and 19,20- DiHDPA) 
negatively correlate with adiposity and a better cardiometabolic 
profile, in young adults. The panel of seven oxylipins is a better 
predictor of adiposity than traditional pro- and anti- inflammatory 
markers. Also, we observed that individuals with obesity have 
higher plasma levels of omega- 6 and lower plasma levels of omega-
 3 oxylipins than normal- weight peers. We would suggest that this 
panel of seven oxylipins may be used as an early diagnostic marker 
for cardiometabolic risk in young adults.O
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